communityacquir
pneumonia
caus
great
mortal
morbid
high
cost
worldwid
empir
select
antibiot
treatment
cornerston
manag
patient
pneumonia
reduc
misus
antibiot
antibiot
resist
sideeff
ect
empir
eff
ectiv
individualis
antibiot
treatment
need
followup
start
antibiot
treatment
also
import
manag
includ
earli
shift
oral
antibiot
stewardship
accord
microbiolog
result
shortdur
antibiot
treatment
account
clinic
stabil
criteria
new
approach
fast
clinic
lung
ultrasound
microbiolog
molecular
biolog
diagnos
promis
communityacquir
pneumonia
associ
earli
late
mortal
increas
rate
cardiovascular
event
studi
need
focu
longterm
manag
pneumonia
absenc
fever
extrapulmonari
manifest
frequent
exampl
patient
pneumonia
due
legionella
spp
present
headach
confus
diarrhoea
clinic
manifest
hyponatraemia
mycoplasma
pneumonia
associ
upper
respiratori
involv
otiti
pharyng
skin
chang
stevensjohnsonlik
syndrom
haemolyt
anaemia
investig
clearli
shown
differenti
typic
atyp
pneumonia
basi
patient
histori
chest
radiograph
reliabl
guidanc
antibiot
treatment
contrast
use
valid
score
antibiot
decis
promis
studi
propos
score
rule
legionella
spp
pneumonia
neg
predict
valu
mani
diseas
syndrom
clinic
sign
symptom
mimic
pneumonia
appendix
probabl
diff
erenti
diagnosi
high
care
assess
need
delay
correct
diagnos
increas
risk
poor
outcom
patient
notsever
communityacquir
pneumonia
main
diff
erenti
diagnosi
upper
respiratori
infect
case
clinician
reli
clinic
evalu
includ
manifest
lrti
focal
chest
sound
exclus
possibl
diagnosi
pointofcar
test
eg
creactiv
protein
crp
patient
sever
communityacquir
pneumonia
monitor
lifethreaten
disord
diff
erenti
pneumonia
noninfecti
disord
acut
heart
failur
occasion
diffi
cult
prompt
start
antibiot
treatment
recommend
biomark
eg
procalcitonin
pct
help
earli
diff
erenti
heart
failur
decompens
avoid
antibiot
misus
diagnosi
pneumonia
exclud
antibiot
treatment
must
stop
dynam
evalu
patient
also
help
clinician
term
manag
eg
pulmonari
infi
ltrate
resolv
complet
posit
pressur
ventil
probabl
due
heart
failur
atelectasi
patient
recurr
pneumonia
underli
diseas
suspect
lung
cancer
metastasi
tuberculosi
foreign
bodi
hypersensit
pneumon
unknown
immunosuppress
statu
global
burden
diseas
studi
report
lrti
remain
second
biggest
caus
death
year
life
lost
agestandardis
death
rate
ci
per
popul
lrti
incid
pneumonia
estim
case
per
personyear
rate
vari
accord
region
season
popul
characterist
term
age
incid
communityacquir
pneumonia
ushapedit
common
children
younger
year
adult
older
year
incid
also
higher
men
boy
women
girl
patient
need
admiss
hospit
mortal
rate
lower
shortterm
mortal
inhospit
day
mortal
hospitalis
patient
rang
howev
patient
intens
care
rate
reach
cost
relat
communityacquir
pneumonia
high
approach
reduc
lengthofstay
adequ
use
antibiot
introduct
vaccin
reduc
cost
far
streptococcu
pneumonia
main
pathogen
caus
communityacquir
pneumonia
worldwid
independ
age
europ
nearli
case
caus
pneumococc
diseas
worldwid
ci
frequent
caus
includ
haemophilu
infl
uenza
account
case
socal
atyp
bacteria
includ
mycoplasma
chlamydia
legionella
spp
caus
case
larg
worldwid
cohort
recent
year
avail
molecular
microbiolog
test
clinic
suspicion
increas
isol
respiratori
virus
communityacquir
pneumonia
adult
virus
particularli
infl
uenza
rhinoviru
coronavirus
caus
third
case
pneumonia
howev
attribut
aetiolog
respiratori
virus
debat
diffi
cult
defi
ne
viru
caus
agent
pneumonia
resist
pneumonia
penicillin
macrolid
nearli
stabl
recent
year
introduct
conjug
pneumococc
vaccin
children
decreas
incid
invas
penicillinresist
case
howev
infect
serotyp
aff
ect
vaccin
increas
incid
mycoplasma
pneumonia
resist
macrolid
vari
greatli
geographi
eg
peak
china
although
proport
patient
infect
pathogen
cover
standard
empir
treatment
low
pathogen
associ
high
mortal
cost
immunocompet
patient
communityacquir
pneumonia
pathogen
frequent
pseudomona
aeruginosa
enterobacteriacea
extendedspectrum
esbl
meticillinresist
staphylococcu
aureu
mrsa
pathophysiolog
healthi
individu
mani
microorgan
colonis
nasopharynx
oropharynx
microaspir
contamin
secret
caus
infect
lower
airway
glottal
refl
exe
presenc
complement
protein
immunoglobulin
secret
peptid
antimicrobi
activ
inhibit
bacteria
bind
protect
lower
airway
healthi
microbiota
upper
airway
also
exert
protect
eff
ect
compet
pathogen
nutrit
resourc
interact
cellular
receptor
use
broadspectrum
antibiot
modifi
microbiota
predispos
infect
interact
virul
pathogen
amount
inoculum
innat
adapt
immun
respons
determin
develop
pneumonia
individu
risk
develop
pneumonia
howev
individu
prone
pneumonia
other
due
intrins
extrins
factor
appendix
new
fi
nding
reveal
individu
genet
variabl
predisposit
develop
pneumonia
clinic
present
exampl
specifi
c
variant
fer
gene
associ
reduc
risk
death
patient
sepsi
due
pneumonia
therebi
fer
gene
might
potenti
target
new
therapi
misch
colleagu
show
polymorph
associ
increas
risk
legionnair
diseas
odd
ratio
ci
patient
clinician
suspect
communityacquir
pneumonia
blood
test
provid
inform
infl
ammatori
state
ie
leucocyt
cell
number
characterist
neutrophilia
crp
associ
organ
damag
ie
acut
renal
failur
sever
diseas
biomark
support
clinician
diff
erenti
bacteri
pneumonia
disord
eg
upper
respiratori
tract
disord
metaanalysi
suggest
antibiot
exposur
reduc
suspect
lrti
via
use
crp
measur
primari
care
risk
ratio
rr
ci
nice
guidelin
recommend
er
antibiot
crp
lower
mgl
primari
care
patient
without
convinc
clinic
diagnosi
communityacquir
pneumonia
pct
high
sensit
moder
specifi
citi
diff
erenti
bacteri
viral
infect
outpati
patient
emerg
depart
inpati
antibiot
encourag
pct
concentr
higher
strongli
encourag
pct
concentr
higher
wherea
discourag
concentr
lower
patient
admit
intens
care
antibiot
treatment
alway
strongli
encourag
pct
concentr
higher
metaanalysi
report
use
pct
guid
antibiot
treatment
pneumonia
result
reduct
exposur
antibiot
median
day
iqr
day
adjust
diff
erenc
day
ci
without
increas
mortal
treatment
failur
moreov
use
pct
guid
antibiot
treatment
reduc
cost
treatment
despit
mani
improv
pathogen
detect
nearli
half
pneumonia
episod
microbiolog
test
recommend
patient
probabl
chang
empir
antibiot
high
reduc
treatment
failur
prevent
antibiot
overus
microbiolog
evalu
fi
gure
recommend
higherrisk
patient
sever
communityacquir
pneumonia
special
disord
eg
asplenia
immunosuppress
hiv
infect
alcohol
abus
sever
sepsi
septic
shock
risk
resist
pathogen
failur
initi
empir
treatment
contrast
recommend
micro
biolog
test
remain
controversi
less
sever
pneumonia
test
expect
littl
eff
ect
antibiot
manag
due
good
respons
empir
treatment
howev
microbiolog
evalu
could
valuabl
surveil
although
posit
blood
pleural
fl
uid
cultur
test
defi
nitiv
identifi
es
pathogen
respons
pneumonia
posit
respiratori
tract
sampl
need
clinic
interpret
microorgan
present
due
colonis
part
healthi
fl
ora
main
diffi
culti
relat
need
highqual
sampl
furthermor
collect
sampl
administr
antibiot
increas
rate
falseneg
result
despit
limit
patient
hospit
purul
sputum
sampl
collect
gram
stain
cultur
recommend
urinari
antigen
use
detect
serotyp
pneumonia
serogroup
legionella
pneumophila
respons
legionella
case
communityacquir
pneumonia
advantag
test
prompt
min
reason
accuraci
abil
detect
infect
patient
receiv
antibiot
therapi
main
drawback
absenc
inform
resist
urinari
antigen
pneumonia
sensit
ci
specifi
citi
l
pneumophila
sensit
specifi
citi
two
randomis
control
trial
test
empir
versu
pathogendirect
antibiot
treatment
urinari
antigen
test
patient
hospit
stabl
pneumonia
shown
diff
erenc
major
outcom
although
conclus
hamper
methodolog
issu
atyp
pathogen
blood
serolog
test
avail
chlamydia
pneumonia
pneumonia
legionella
spp
howev
clinic
use
limit
delay
result
diffi
culti
interpret
pcr
test
avail
bacteri
caus
relat
mycoplasma
chlamydia
streptococcu
legionella
spp
done
bronchoalveolar
lavag
fl
uid
nasopharyng
swab
realtim
multiplexpanel
pcr
aim
provid
result
hour
promis
method
fast
bacteri
aetiolog
diagnos
communityacquir
pneumonia
howev
costeff
ectiv
unclear
data
resist
pcr
test
avail
sever
respiratori
virus
view
controversi
use
antivir
therapi
diffi
culti
relat
diagnosi
viral
pneumonia
costeff
ectiv
clinician
reserv
test
virus
special
group
patient
within
infl
uenza
season
thorac
imag
essenti
sever
aspect
pneumonia
manag
chest
radiograph
diagnost
accuraci
alveolar
consolid
pleural
eff
usion
consid
ct
gold
standard
techniqu
perform
posteroanterior
laterolater
project
increas
accuraci
contrast
chest
radiograph
less
accuraci
bedridden
obes
sever
immunosuppress
patient
patient
previou
alter
chest
radiograph
provid
detail
inform
lung
parenchyma
media
stinum
also
reveal
altern
diagnos
howev
ct
limit
includ
increas
cost
radiat
exposur
imposs
ct
bedsid
reason
ct
reserv
specifi
c
situat
exclud
presenc
diagnos
eg
pulmonari
embol
suspicion
fungal
lung
infect
present
patient
unclear
chest
radiograph
eg
occult
pneumonia
chronic
obstruct
pulmonari
diseas
nonrespond
pneumonia
detect
complic
eg
lung
abscess
lung
ultrasound
use
method
evalu
respiratori
diseas
includ
pneumonia
recent
metaanalysi
show
sensit
ci
specifi
citi
diagnosi
pneumonia
adult
compar
previou
method
lung
ultrasound
advantag
radiationfre
done
bedsid
pregnant
woman
allow
dynam
evalu
increas
accuraci
detect
consolid
pleural
eff
usion
compar
chest
radiograph
take
less
time
lung
ultrasound
limit
learn
curv
repeat
oper
depend
earli
evalu
patient
communityacquir
pneumonia
two
question
need
answer
patient
need
admit
hospit
treat
intens
care
decis
need
made
earli
wide
shown
late
admiss
intens
care
associ
increas
mortal
contrast
admiss
patient
treat
outsid
hospit
associ
increas
cost
risk
develop
nosocomi
infect
clinic
judgment
main
determin
siteofcar
decis
oxygen
satur
arteri
ga
analysi
give
import
inform
sever
eg
consid
safer
cutoff
hospit
admiss
furthermor
score
biomark
assist
clinic
judgment
pneumonia
sever
index
psi
frequent
use
score
psi
compos
item
classifi
es
patient
fi
categori
sever
associ
risk
mortal
age
comorbid
highli
weight
psi
reason
psi
underestim
sever
pneumonia
young
patient
without
previou
diseas
use
fi
item
practic
calcul
although
account
comorbid
import
consider
includ
either
score
socioeconom
statu
social
support
aff
ect
outcom
psi
develop
predict
complic
associ
communityacquir
pneumonia
clinic
research
need
develop
specifi
c
score
predict
event
patient
admit
intens
care
requir
mechan
ventil
vasopressor
major
criteria
sever
pneumonia
american
thorac
societi
infecti
diseas
societi
america
guidelin
addit
major
criteria
nine
minor
criteria
includ
predict
admiss
intens
care
metaanalysi
propos
simplifi
cation
american
thorac
societi
infecti
diseas
societi
america
minor
criteria
remov
three
variabl
thrombocytopenia
hypothermia
leucopenia
similar
accuraci
use
score
use
predict
admiss
intens
care
smartcop
reaicu
late
admiss
biomark
increas
perform
score
predict
icu
admiss
eg
proadrenomedullin
identifi
sever
communityacquir
pneumonia
eg
crp
biomark
also
identifi
patient
fi
rst
admit
ward
might
need
admiss
intens
care
later
antibiot
treatment
typic
chosen
empir
absenc
microbiolog
result
upon
diagnosi
choic
empir
antibiot
depend
like
pathogen
individu
risk
factor
comorbid
allergi
costeff
ectiv
appendix
figur
tabl
describ
manag
antibiot
treatment
propos
communityacquir
sever
studi
shown
reduct
mortal
guidelin
follow
guidelin
suggest
coverag
pneumonia
atyp
pathogen
eg
combin
plu
macrolid
respiratori
fl
ouroquinolon
howev
dual
coverag
still
debat
three
metaanalys
report
diff
erent
result
mortal
furthermor
concern
exist
sideeff
ect
increas
risk
cardiovascular
event
patient
receiv
macrolid
select
pressur
resist
macrolid
fl
uoroquinolon
two
recent
randomis
control
trial
provid
import
result
antibiot
treatment
peopl
admit
hospit
nonsever
communityacquir
pneumonia
clustercrossov
trial
assess
noninferior
versu
plu
macrolid
versu
fl
uoroquinolon
regimen
day
mortal
primari
outcom
includ
patient
clinic
suspect
pneumonia
treat
nonintensivecareunit
ward
monotherapi
inferior
antibiot
regimen
anoth
noninferior
openlabel
trial
randomli
assign
patient
moder
sever
communityacquir
pneumonia
receiv
plu
macrolid
studi
unabl
show
noninferior
clinic
stabil
day
treatment
nevertheless
nonsignifi
cant
trend
superior
shown
favour
dual
therapi
betweengroup
diff
erenc
twosid
ci
sever
communityacquir
pneumonia
coverag
typic
atyp
pathogen
seem
protect
mortal
recommend
major
guidelin
macrolid
seem
addit
benefi
ts
due
immuno
modulatori
eff
ect
sever
communityacquir
pneumonia
small
proport
patient
specifi
c
pathogen
requir
diff
erent
treatment
respond
standard
empir
treatment
reason
american
thorac
societi
infecti
diseas
societi
america
nosocomi
pneumonia
guidelin
introduc
new
categori
pneumonia
call
healthcareassoci
pneumonia
help
clinician
select
patient
need
extendedspectrum
antibiot
due
high
probabl
resist
pathogen
defi
nition
wide
criticis
mani
limit
studi
shown
accur
detect
atrisk
patient
score
develop
better
accuraci
howev
also
limit
still
need
strong
extern
valid
summari
risk
factor
resist
pathogen
contain
appendix
resist
pathogen
diff
erent
treatment
score
base
specifi
c
risk
factor
pathogen
might
use
method
compar
gener
defi
nition
anoth
concern
relat
treatment
patient
risk
resist
pneumococcu
elderli
patient
age
year
receiv
recent
therapi
macrolid
fl
uoroquinolon
alcohol
consumpt
immunosuppress
appendix
new
antibiot
urgent
need
infect
spread
resist
set
recent
phase
trial
show
promis
result
ceftarolin
fosamil
fi
fthgener
cephalosporin
activ
mrsa
treatment
communityacquir
pneumonia
psi
iiiiv
asian
patient
among
macrolid
solithro
mycin
potenti
new
antibiot
activ
macrolideresist
bacteria
effi
caci
neuraminidas
inhibitor
prevent
treat
infl
uenza
pneumonia
still
controversi
patient
infl
uenza
recent
metaanalysi
fl
uoroquinolon
limit
situat
option
prescrib
ineff
ectiv
eg
hepatotox
skin
reaction
cardiac
arrhythmia
tendon
ruptur
drug
includ
cefotaxim
ceftriaxon
ampicillinsulbactam
includ
coamoxiclav
cefotaxim
ceftarolin
fosamil
ceftriaxon
cefuroxim
piperacillintazobactam
cephalosporin
eg
cefotaxim
ceftriaxon
fi
rst
dose
antibiot
given
soon
possibl
diagnosi
communityacquir
pneumonia
antibiot
start
prefer
within
fi
rst
h
hospit
arriv
shorter
time
fi
rst
dose
antibiot
marker
qualiti
care
howev
metaanalysi
stabl
patient
communityacquir
pneumonia
reveal
administr
within
h
associ
lower
mortal
ci
pressur
rapid
antibiot
administr
associ
increas
risk
misdiagnosi
increas
risk
advers
eff
ect
unstabl
patient
sever
sepsi
septic
shock
time
fi
rst
dose
strongli
associ
reduct
mortal
administr
fi
rst
hour
diagnosi
recommend
pneumonia
main
caus
sepsi
worldwid
sever
sepsi
septic
shock
previou
aspect
care
prioriti
ie
assess
pathogen
antibiot
whether
earli
intens
care
unit
admiss
need
surviv
sepsi
campaign
also
advoc
measur
lactat
concentr
diagnosi
prompt
initi
expans
mlkg
crystalloid
hypotens
lactat
concentr
mmoll
higher
result
relat
recommend
earli
goaldirect
therapi
controversi
mainli
insuffi
cient
benefi
ts
report
well
design
multicentr
randomis
control
trial
major
concern
patient
sepsi
due
pneumonia
risk
associ
cumul
fl
uid
balanc
blood
transfus
worsen
respiratori
function
patient
acut
respiratori
failur
due
pneumonia
must
assess
earli
need
respiratori
support
oxygen
satur
import
marker
outcom
patient
sever
pneumonia
candid
invas
mechan
ventil
delay
lead
increas
mortal
patient
moder
sever
diseas
cautious
manag
use
noninvas
ventil
train
staff
metaanalysi
suggest
appropri
use
noninvas
ventil
pneumonia
reduc
need
endotrach
intub
ci
intens
care
unit
mortal
lengthofstay
intens
care
unit
mean
ci
howev
metaanalysi
includ
patient
three
randomis
trial
benefi
ts
particularli
evid
patient
chronic
obstruct
pulmonari
diseas
immunosuppress
noninvas
ventil
also
consid
palli
treatment
patient
termin
ill
mechan
ventil
patient
protect
ventil
strongli
recommend
diagnosi
acut
respiratori
distress
syndrom
less
sever
pneumonia
protect
ventil
also
seem
prevent
progress
lung
injuri
use
corticosteroid
communityacquir
pneumonia
debat
especi
aff
ect
mortal
metaanalys
report
reduc
hospit
lengthofstay
mean
day
ci
use
corticosteroid
multicentr
randomis
control
trial
show
shorter
time
reach
clinic
stabil
patient
pneumonia
receiv
oral
prednison
mg
day
day
relat
placebo
group
day
vs
day
hazard
ratio
ci
anoth
multicentr
randomis
control
trial
show
methylprednisolon
mgkg
per
h
day
reduc
risk
treatment
failur
compar
placebo
ci
patient
sever
communityacquir
pneumonia
high
baselin
concentr
crp
mortal
updat
metaanalys
report
conclus
result
hospitalis
patient
although
corticosteroid
associ
better
surviv
subgroup
sever
communityacquir
pneumonia
howev
trial
includ
metaanalys
small
high
heterogen
insuffi
cient
power
assess
mortal
defi
nitiv
data
avail
best
type
dose
corticosteroid
patient
communityacquir
pneumonia
whether
given
continu
intermitt
taper
scheme
clinician
awar
possibl
steroidinduc
sideeff
ect
patient
control
set
eg
randomis
control
trial
hyperglycaemia
frequent
report
patient
communityacquir
pneumonia
receiv
corticosteroid
howev
larg
trial
includ
patient
sever
sepsi
septic
shock
communityacquir
pneumonia
main
sourc
infect
show
steroid
sideeff
ect
superinfect
investig
propos
statin
adjunct
therapi
pneumonia
due
antiinfl
ammatori
activ
abil
reduc
cardiovascular
event
eff
ect
controversi
initi
manag
communityacquir
pneumonia
subsequ
day
fundament
good
outcom
highqual
manag
need
multidimension
approach
fi
gure
evalu
clinic
stabil
appendix
fundament
aspect
communityacquir
pneumonia
care
stabil
criteria
er
inform
antibiot
treatment
eg
appropri
treatment
switch
oral
medic
short
antibiot
treatment
durat
indic
hospit
discharg
reduc
hospit
lengthofstay
stewardship
microbiolog
test
becom
avail
import
reevalu
antibiot
treatment
antibiot
adapt
accord
antibiogram
result
narrow
accord
identifi
ed
pathogen
discontinu
diagnosi
pneumonia
unlik
stewardship
fundament
avoid
continu
unnecessari
treatment
increas
select
pressur
resist
reduc
risk
unnecessari
complic
eg
clostridium
diffi
cile
infect
patient
hospit
communityacquir
pneumonia
began
treatment
intraven
antibiot
switch
oral
therapi
consid
patient
reach
clinic
stabil
two
randomis
control
trial
shown
diff
erenc
mortal
import
reduct
lengthofstay
advers
drug
reaction
patient
switch
oral
therapi
earli
day
treatment
given
lowsever
pneumonia
clinic
stabil
day
treatment
day
given
sever
pneumonia
adapt
depend
improv
symptom
stabil
inde
two
metaanalys
report
similar
effi
caci
shortcours
day
longcours
day
treatment
patient
sever
pneumonia
exclud
addit
observ
studi
robust
analys
report
similar
outcom
shortcours
longcours
antibiot
treatment
patient
sever
communityacquir
pneumonia
patient
extra
pulmonari
complic
empyema
pneu
monia
due
specifi
c
pathogen
eg
legionella
spp
mrsa
seem
benefi
ts
prolong
treatment
biomark
use
guid
antibiot
durat
onetim
pct
valu
lower
decreas
peak
strong
indic
antibiot
discontinu
randomis
control
trial
compar
pct
crp
antibiot
guidanc
patient
sever
sepsi
septic
shock
show
similar
outcom
howev
studi
need
compar
costeff
ectiv
among
biomark
patient
communityacquir
pneumonia
present
deterior
known
clinic
failur
predict
mortal
therefor
defi
nition
caus
failur
essenti
earli
failur
h
seem
relat
sever
primari
infect
eg
develop
septic
shock
wherea
late
failur
h
tend
due
secondari
event
eg
nosocomi
superinfect
exacerb
comorbid
develop
sever
sepsi
primari
reason
failur
outpati
also
need
earli
followup
h
detect
develop
failur
nonrespond
pneumonia
diff
erent
disord
compris
persist
pulmonari
infi
ltrate
month
symptom
onset
due
mani
caus
presenc
lung
cancer
underli
lung
diseas
patient
hospit
seem
benefi
earli
mobilis
rehabilit
followup
outcom
patient
admit
hospit
communityacquir
pneumonia
readmit
within
day
half
case
comorbid
caus
readmiss
mainli
cardiovascular
pulmonari
neurolog
diseas
wherea
patient
new
episod
pneumonia
caus
readmiss
main
risk
factor
readmiss
initi
treatment
failur
clinic
instabl
hospit
discharg
older
age
comorbid
impair
function
statu
longterm
mortal
pneumonia
caus
much
shortterm
longterm
mortal
mortal
patient
communityacquir
pneumonia
higher
infect
communityacquir
pneumonia
associ
increas
risk
cardiovascular
complic
explanatori
reason
includ
hypoxaemia
infl
ammat
prothrombot
statu
pathogenspecifi
c
factor
host
characterist
metaanalysi
incid
cardiac
event
within
day
hospit
admiss
communityacquir
pneumonia
report
cumul
rate
heart
failur
rang
arrhythmia
rate
rang
acut
coronari
syndrom
rate
rang
clinician
pay
attent
regard
modifi
factor
avail
decreas
risk
new
episod
communityacquir
pneumonia
appendix
infl
uenza
vaccin
robustli
associ
reduc
rate
pneumonia
better
outcom
studi
individu
older
year
report
reduct
rate
pneumonia
infl
uenza
infect
follow
reduct
allcaus
mortal
two
vaccin
avail
pneumonia
pneumococc
polysaccharid
vaccin
pneumococc
conjug
vaccin
pneumococc
polysaccharid
vaccin
contain
polysaccharid
pneumococc
serotyp
recent
version
pneumococc
conjug
vaccin
contain
serotyp
comparison
pneumococc
polysaccharid
vaccin
pneumococc
conjug
vaccin
seem
induc
stronger
longerlast
secondari
immun
respons
booster
eff
ect
result
recent
metaanalysi
show
strong
evid
recommend
pneumococc
polysaccharid
vaccin
prevent
invas
pneumococc
diseas
adult
nevertheless
less
clear
evid
effi
caci
prevent
nonbacteraem
pneumonia
patient
chronic
ill
reduct
allcaus
pneumonia
mortal
pneumococc
conjug
approv
clinic
use
adult
us
european
agenc
capita
studi
doubleblind
randomis
placebocontrol
clinic
trial
involv
nearli
adult
older
year
show
clinic
effi
caci
pneumococc
conjug
prevent
fi
rst
episod
vaccineserotyp
pneumococc
communityacquir
pneumonia
includ
nonbacteraem
pneumonia
invas
pneumococc
diseas
howev
trial
exclud
immunosuppress
patient
previous
vaccin
person
substanti
number
case
pneumonia
caus
serotyp
includ
panel
controversi
uncertainti
implement
rapid
diagnost
test
use
pcr
techniqu
virus
bacteria
might
increas
number
microbiolog
diagnos
consequ
number
initi
appropri
treatment
although
devic
abl
provid
rapid
diagnos
well
design
studi
need
investig
major
outcom
costeff
ectiv
real
rate
diff
erent
treat
pathogen
communityacquir
pneumonia
pseudomona
aeruginosa
enterobacteriacea
extendedspectrum
meticillinresist
staphylococcu
aureu
diff
er
contin
countri
eg
usa
japan
vs
europ
concept
healthcareassoci
pneumonia
accur
result
excess
administr
broadspectrum
antibiot
risk
factor
microorgan
describ
recent
implement
clinic
practic
still
lack
combin
antibacteri
therapi
matter
debat
therapi
recommend
patient
communityacquir
pneumonia
admit
intens
care
unit
patient
bacteraem
streptococcu
pneumonia
furthermor
patient
high
mortal
admit
ward
might
benefi
treatment
strategi
recent
data
randomis
control
trial
show
reduct
time
clinic
stabil
treatment
failur
patient
communityacquir
pneumonia
receiv
corticosteroid
howev
data
controversi
eff
ect
mortal
prematur
halt
trial
sever
communityacquir
pneumonia
reveal
import
decreas
mortal
vs
longterm
cardiovascular
complic
patient
communityacquir
pneumonia
complet
understood
seem
residu
infl
ammat
might
import
role
trigger
procoagul
pathway
lead
cardiovascular
complic
panel
outstand
research
question
intervent
studi
need
microbiolog
test
techniqu
increas
rate
initi
appropri
treatment
would
result
improv
outcom
reduc
overus
antibiot
valid
studi
use
risk
factor
diff
erenttotreat
microorgan
confi
rm
accuraci
risk
factor
implement
clinic
practic
also
need
intervent
studi
done
assess
costeff
ectiv
creactiv
protein
procalcitonin
lowincom
middleincom
countri
specifi
c
set
randomis
control
trial
need
patient
sever
communityacquir
pneumonia
admit
intens
care
unit
compar
monotherapi
respiratori
quinolon
combin
therapi
plu
macrolid
investig
larg
randomis
control
trial
patient
communityacquir
pneumonia
admit
intens
care
unit
assess
administr
corticosteroid
versu
placebo
power
address
mortal
qualityoflif
outcom
studi
sever
communityacquir
pneumonia
need
anim
model
human
be
test
new
coadjut
treatment
enrich
immunoglobulin
monoclon
antibodi
molecul
block
endotoxin
exotoxin
microb
prospect
observ
followup
studi
patient
communityacquir
pneumonia
need
better
describ
clinic
biolog
risk
factor
cardiovascular
complic
design
pharmacolog
randomis
control
trial
pneumococc
conjug
invas
pneumococc
diseas
us
us
center
diseas
control
prevent
recommend
administr
pneumococc
conjug
pneumococc
polysaccharid
seri
adult
age
year
older
panel
outstand
research
question
remain
address
futur
larg
trial
panel
